Patient‐optimized doses of fesoterodine improve bladder symptoms in an open‐label, flexible‐dose study
Authors: Wyndaele Jean‐Jacques , Goldfischer Evan R. , Morrow Jon D. , Gong Jason , Tseng Li‐Jung , Choo Myung‐Soo 
Published: September 2010

Study Type – Therapy (cohort)

Level of Evidence 2b

What’s known on the subject? and What does the study add?

We know that bladder‐relaxing agents antimuscrinics act on symptoms of overactive bladder and are the first treatment in such patients. We know that fesoterodine is a newer antimuscarinic with a good activity safety profile.

This study adds to the experience that changing the dose of antimuscrinics as fesoterodine is often needed by patients, that the decision can be made by the patients, and the change in dose adds to the clinical result.

OBJECTIve

To assess changes in overactive bladder (OAB) symptoms and patient‐reported outcomes in a post hoc analysis in which subjects from a 12‐week, open‐label, flexible‐dose fesoterodine study were stratified according to whether they opted for dose escalation.

PATIENTS AND METHODS

Subjects with OAB (eight or more micturitions and three or more urgency episodes per 24 h) who reported dissatisfaction with tolterodine within 2 years of screening received fesoterodine 4 mg once daily for 4 weeks, with an optional dose increase to 8 mg after week 4 based on discussion of efficacy and tolerability between the subject and investigator. Subjects completed 5‐day diaries, the Patient Perception of Bladder Condition (PPBC) and Urgency Perception Scale (UPS) at baseline and weeks 4 and 12, and the Overactive Bladder Questionnaire (OAB‐q) at baseline and week 12. Subjects rated treatment satisfaction at week 12.

RESULTS

Dose escalation to 8 mg at week 4 was chosen by 255 (50%) of 513 subjects. At baseline, subjects who opted for dose escalation at week 4 (escalators) had significantly higher means for all diary variables except urgency urinary incontinence (UUI) episodes, significantly greater OAB‐q Symptom Bother scores and significantly lower OAB‐q health‐related quality of life (HRQL) scores (all P < 0.05) compared to subjects who did not opt for dose escalation (non‐escalators). There was no significant difference in the percentage of escalators (51%) and non‐escalators (48%) who reported at least one UUI episode on baseline diary. At week 4 (before the decision to escalate was made), all outcomes were significantly improved vs baseline among both groups (all P < 0.0001), although non‐escalators had significantly greater improvements in all diary variables and in PPBC and UPS scores than escalators (all P < 0.05), and the 5‐day diary‐dry rate (i.e. the percentage of subjects with at least one UUI episode on baseline diary and no UUI episodes on week 4 diary) was significantly higher (P= 0.0016) among non‐escalators (62%) than among escalators (42%). At week 12, all outcomes were again significantly improved vs baseline among both groups (all P < 0.0001). There were no significant differences between non‐escalators and escalators in week 12 improvements for most diary variables, UPS scores, OAB‐q Symptom Bother scores, the diary‐dry rate (68% vs 60%) or the percentage of subjects who reported treatment satisfaction (82% vs 78%). However, escalators still had significantly greater improvements from baseline in urgency episodes, PPBC scores and OAB‐q total HRQL and Coping domains (P < 0.05). Adverse event rates were similar between non‐escalators and escalators. Dry mouth was the most frequently reported adverse event; most cases were mild.

CONCLUSION

Flexible‐dose fesoterodine significantly improved OAB symptoms and patient‐reported outcomes in subjects who chose to remain on the initial 4‐mg dose, as well as in the 50% of subjects who escalated to the 8‐mg dose after 4 weeks. Non‐escalators had significantly fewer OAB symptoms at baseline and significantly greater improvements than escalators before dose escalation. Escalators showed increased symptom relief after dose escalation; improvements in most outcomes were similar among non‐escalators and escalators by week 12. Flexible‐dose fesoterodine was well tolerated, with similar adverse‐event profiles observed in the escalator and non‐escalator groups. These results may help clinicians to identify patients more likely to require fesoterodine 8 mg to achieve maximum relief of OAB symptoms and thus facilitate dose escalation in these patients.